Cargando…

Point prevalence and clinical course of proteinuria in dogs with idiopathic non‐erosive immune‐mediated polyarthritis

OBJECTIVES: To describe the point prevalence and clinical course of proteinuria in dogs diagnosed with idiopathic non‐erosive immune‐mediated polyarthritis. MATERIALS AND METHODS: Cases presenting to a single referral centre with a diagnosis of idiopathic non‐erosive immune‐mediated polyarthritis we...

Descripción completa

Detalles Bibliográficos
Autores principales: Barker, L., McManus, S., Adamantos, S., Black, V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542946/
https://www.ncbi.nlm.nih.gov/pubmed/35508589
http://dx.doi.org/10.1111/jsap.13503
_version_ 1784804262683869184
author Barker, L.
McManus, S.
Adamantos, S.
Black, V.
author_facet Barker, L.
McManus, S.
Adamantos, S.
Black, V.
author_sort Barker, L.
collection PubMed
description OBJECTIVES: To describe the point prevalence and clinical course of proteinuria in dogs diagnosed with idiopathic non‐erosive immune‐mediated polyarthritis. MATERIALS AND METHODS: Cases presenting to a single referral centre with a diagnosis of idiopathic non‐erosive immune‐mediated polyarthritis were retrospectively recruited from January 2009 to August 2018. Data including signalment, urinalysis, clinicopathological results, cytology from arthrocentesis, treatment and long‐term follow‐up were analysed. Dogs were defined as: non‐proteinuric (UPC <0.2), borderline proteinuric (UPC 0.2‐0.5) or overtly proteinuric (UPC >0.5). RESULTS: Fifty‐eight dogs met the inclusion criteria. Twenty‐two dogs were overtly proteinuric (38%), eight dogs were borderline proteinuric (14%) and 28 dogs were non‐proteinuric (48%). Repeated urinalysis was performed in nine of 12 dogs with UPC greater than 2.0. The UPC decreased in all nine dogs, with the UPC decreasing to less than 0.5 in 44% of dogs. A greater than 50% decrease in UPC was noted in 44% of dogs, despite seven of nine (77%) receiving prednisolone as either monotherapy or in conjunction with an adjunctive immunosuppressive medication. CLINICAL SIGNIFICANCE: Proteinuria was common in this cohort of dogs diagnosed with primary idiopathic non‐erosive immune‐mediated polyarthritis. The use of prednisolone does not appear to be contraindicated in proteinuric dogs with idiopathic non‐erosive immune‐mediated polyarthritis.
format Online
Article
Text
id pubmed-9542946
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-95429462022-10-14 Point prevalence and clinical course of proteinuria in dogs with idiopathic non‐erosive immune‐mediated polyarthritis Barker, L. McManus, S. Adamantos, S. Black, V. J Small Anim Pract Original Articles OBJECTIVES: To describe the point prevalence and clinical course of proteinuria in dogs diagnosed with idiopathic non‐erosive immune‐mediated polyarthritis. MATERIALS AND METHODS: Cases presenting to a single referral centre with a diagnosis of idiopathic non‐erosive immune‐mediated polyarthritis were retrospectively recruited from January 2009 to August 2018. Data including signalment, urinalysis, clinicopathological results, cytology from arthrocentesis, treatment and long‐term follow‐up were analysed. Dogs were defined as: non‐proteinuric (UPC <0.2), borderline proteinuric (UPC 0.2‐0.5) or overtly proteinuric (UPC >0.5). RESULTS: Fifty‐eight dogs met the inclusion criteria. Twenty‐two dogs were overtly proteinuric (38%), eight dogs were borderline proteinuric (14%) and 28 dogs were non‐proteinuric (48%). Repeated urinalysis was performed in nine of 12 dogs with UPC greater than 2.0. The UPC decreased in all nine dogs, with the UPC decreasing to less than 0.5 in 44% of dogs. A greater than 50% decrease in UPC was noted in 44% of dogs, despite seven of nine (77%) receiving prednisolone as either monotherapy or in conjunction with an adjunctive immunosuppressive medication. CLINICAL SIGNIFICANCE: Proteinuria was common in this cohort of dogs diagnosed with primary idiopathic non‐erosive immune‐mediated polyarthritis. The use of prednisolone does not appear to be contraindicated in proteinuric dogs with idiopathic non‐erosive immune‐mediated polyarthritis. Blackwell Publishing Ltd 2022-05-04 2022-08 /pmc/articles/PMC9542946/ /pubmed/35508589 http://dx.doi.org/10.1111/jsap.13503 Text en © 2022 The Authors. Journal of Small Animal Practice published by John Wiley & Sons Ltd on behalf of British Small Animal Veterinary Association https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Barker, L.
McManus, S.
Adamantos, S.
Black, V.
Point prevalence and clinical course of proteinuria in dogs with idiopathic non‐erosive immune‐mediated polyarthritis
title Point prevalence and clinical course of proteinuria in dogs with idiopathic non‐erosive immune‐mediated polyarthritis
title_full Point prevalence and clinical course of proteinuria in dogs with idiopathic non‐erosive immune‐mediated polyarthritis
title_fullStr Point prevalence and clinical course of proteinuria in dogs with idiopathic non‐erosive immune‐mediated polyarthritis
title_full_unstemmed Point prevalence and clinical course of proteinuria in dogs with idiopathic non‐erosive immune‐mediated polyarthritis
title_short Point prevalence and clinical course of proteinuria in dogs with idiopathic non‐erosive immune‐mediated polyarthritis
title_sort point prevalence and clinical course of proteinuria in dogs with idiopathic non‐erosive immune‐mediated polyarthritis
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542946/
https://www.ncbi.nlm.nih.gov/pubmed/35508589
http://dx.doi.org/10.1111/jsap.13503
work_keys_str_mv AT barkerl pointprevalenceandclinicalcourseofproteinuriaindogswithidiopathicnonerosiveimmunemediatedpolyarthritis
AT mcmanuss pointprevalenceandclinicalcourseofproteinuriaindogswithidiopathicnonerosiveimmunemediatedpolyarthritis
AT adamantoss pointprevalenceandclinicalcourseofproteinuriaindogswithidiopathicnonerosiveimmunemediatedpolyarthritis
AT blackv pointprevalenceandclinicalcourseofproteinuriaindogswithidiopathicnonerosiveimmunemediatedpolyarthritis